Built in the rate -based model, Welcure Drugs & Pharmaceuticals will obtain a 5% fixed commission on the cost of goods.
Welcure Drugs & Pharmaceuticals has signed a definitive mandate with the company Fortune SailandSagar Impex for supply and acquisition services of third parties.
The mandate, valued at ₹ 517 million rupees, is structured under an ex -works model and represses a significant milestone in the growth strategy led by Welcure services.
According to the mandate, Welcure Drugs & Pharmaceuticals LTD will participate in the supply and the acquisition of multiple sku of finished dosing. Built in the rate -based model, the company will obtain a 5 percent fixed commission on the cost of goods. The estimated service of ₹ 26 million rupees in fiscal year 26 is expected, said the company.
The mandate improves the welcure -based wallet without the incremental exposure of the balance sheet, which makes this an opportunity for high margin growth, he added.
The buyer, Fortune Sagar Impex Company, Thailand, will be responsible for responsibilities related to packaging, labeling, container, insurance, loading and all regulatory authorizations of the destination countries.